DA
ATNM icon

DCM Advisors’s Actinium Pharmaceuticals ATNM Stock Holding History

DCM Advisors’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-13,300
Closed -$104K – 238
2020
Q4 		$104K Buy
+13,300
New +$144K 0.06% 206

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

DCM Advisors's ATNM Position: Q1 2021 in Review

DCM Advisors sold out of Actinium Pharmaceuticals (ATNM) in Q1 2021, closing a stake of 13,300 shares — an estimated $104K sold.

DCM Advisors first reported a position in ATNM in Q4 2020 and held it in 1 quarter. The position peaked at $104K in Q4 2020. 40 funds tracked by Wall St. Rank hold ATNM as of Q1 2021.

  • DCM Advisors reported no remaining Actinium Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • DCM Advisors sold 13,300 Actinium Pharmaceuticals shares in Q1 2021, an estimated $104K.
  • DCM Advisors first reported a position in Actinium Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • DCM Advisors's Actinium Pharmaceuticals position peaked at $104K in Q4 2020.
  • 40 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2021.

Based on DCM Advisors's 13F filing for Q1 2021, filed 17 May 2021.